Hepatology International

, Volume 7, Issue 3, pp 859–868 | Cite as

Roles of alcohol drinking pattern in fatty liver in Japanese women

  • Akio Moriya
  • Yoshiaki Iwasaki
  • Souhei Ohguchi
  • Eizo Kayashima
  • Tadahiko Mitsumune
  • Fusao Ikeda
  • Masaharu Ando
  • Kazuhide Yamamoto
Original Article



Several studies have reported an inverse association between moderate alcohol consumption and prevalence of fatty liver (FL) in men. We aimed to clarify this association in women.


We collected health checkup data from 4,921 Japanese women without concurrent liver disease (mean age 46.4 years) and performed a cross-sectional study to evaluate the influence of alcohol drinking patterns (frequency and amount) on the prevalence of FL as assessed by ultrasonography.


Alcohol consumption was reported in 30.8 % of participants, and FL was observed in 13.8 % (15.5 % nondrinkers, 10.1 % drinkers). Alcohol consumption was inversely associated with FL prevalence [adjusted odds ratio (AOR) 0.79, 95 % confidence interval (CI) 0.63–0.98]. In analyses stratified by drinking frequency and/or amount of alcohol consumed, the risk of FL decreased for the following categories: 0.1–19.9 g/drinking day (AOR 0.61, 95 % CI 0.44–0.83) and 0.1–69.9 g/week (AOR 0.74, 95 % CI 0.55–0.98). The amount of alcohol consumed directly correlated with the prevalence of FL in daily drinkers (p < 0.05), whereas there was no correlation between the frequency of alcohol consumption and FL prevalence. Alanine aminotransferase levels were significantly lower for the following categories: 0.1–19.9 g/drinking day for 1–3 days a week (p = 0.016) and 0.1–69.9 g within 1–3 drinking days a week (p = 0.004).


Minimal alcohol consumption appears to have protective effects against nonalcoholic FL disease in women, although an increase in the amount of alcohol consumed appears to nullify the protective effect.


Nonalcoholic fatty liver disease Metabolic syndrome Alcohol consumption Drinking frequency Ultrasonography 



No financial support was received.

Conflict of interest

Akio Moriya, Yoshiaki Iwasaki, Souhei Ohguchi, Eizo Kayashima, Tadahiko Mitsumune, Fusao Ikeda, Masaharu Ando, and Kazuhide Yamamoto declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

Compliance with ethical requirements

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100CrossRefPubMedGoogle Scholar
  2. 2.
    Suzuki A, Angulo P. St Sauver J, Muto A, Okada T, Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 2007;102:1912–1919CrossRefPubMedGoogle Scholar
  3. 3.
    Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947–1954CrossRefPubMedGoogle Scholar
  4. 4.
    Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol 2009;104:2189–2195CrossRefPubMedGoogle Scholar
  5. 5.
    Yamada T, Fukatsu M, Suzuki S, Yoshida T, Tokudome S, Joh T. Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. Dig Dis Sci 2010;55:176–182CrossRefPubMedGoogle Scholar
  6. 6.
    Hiramine Y, Imamura Y, Uto H, Koriyama C, Horiuchi M, Oketani M, et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J Gastroenterol 2011;46:519–528CrossRefPubMedGoogle Scholar
  7. 7.
    Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:378–388CrossRefPubMedGoogle Scholar
  8. 8.
    Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997;41:845–850Google Scholar
  9. 9.
    You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 2004;287:G1–G6CrossRefPubMedGoogle Scholar
  10. 10.
    Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995;310:555–559CrossRefPubMedGoogle Scholar
  11. 11.
    Conigrave KM, Hu BF, Camargo CA Jr, Stampfer MJ, Willett WC, Rimm EB. A prospective study of drinking patterns in relation to risk of type 2 diabetes among men. Diabetes 2001;50:2390–2395CrossRefPubMedGoogle Scholar
  12. 12.
    Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003;348:109–118CrossRefPubMedGoogle Scholar
  13. 13.
    Tolstrup J, Jensen MK, Tjønneland A, Overvad K, Mukamal KJ, Grønbaek M. Prospective study of alcohol drinking patterns and coronary heart disease in women and men. BMJ 2006;332:1244–1248CrossRefPubMedGoogle Scholar
  14. 14.
    Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498–3504CrossRefPubMedGoogle Scholar
  15. 15.
    Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421–427CrossRefPubMedGoogle Scholar
  16. 16.
    Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006;9:637–642CrossRefPubMedGoogle Scholar
  17. 17.
    Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007;13:2193–2198CrossRefPubMedGoogle Scholar
  18. 18.
    Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722–728CrossRefPubMedGoogle Scholar
  19. 19.
    Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73–80CrossRefPubMedGoogle Scholar
  20. 20.
    Mumenthaler MS, Taylor JL, O’Hara R, Yesavage JA. Gender differences in moderate drinking effects. Alcohol Res Health. 1999;23:55–64.PubMedGoogle Scholar
  21. 21.
    Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J 2002;66:987–992Google Scholar
  22. 22.
    Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009;51:1061–1067CrossRefPubMedGoogle Scholar
  23. 23.
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. http://www.R-project.org/. Retrieved 27 Oct 2012
  24. 24.
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10Google Scholar
  25. 25.
    Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248–250CrossRefPubMedGoogle Scholar
  26. 26.
    Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025–1029CrossRefPubMedGoogle Scholar
  27. 27.
    Facchini F, Chen YD, Reaven GM. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care 1994;17:115–119CrossRefPubMedGoogle Scholar
  28. 28.
    Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 2002;287:2559–2562CrossRefPubMedGoogle Scholar
  29. 29.
    Avogaro A, Watanabe RM, Dall’Arche A, De Kreutzenberg SV, Tiengo A, Pacini G. Acute alcohol consumption improves insulin action without affecting insulin secretion in type 2 diabetic subjects. Diabetes Care 2004;27:1369–1374CrossRefPubMedGoogle Scholar
  30. 30.
    Mendeloff AI. Effect of intravenous infusions of ethanol upon estimated hepatic blood flow in man. J Clin Invest 1954;33:1298–1302CrossRefPubMedGoogle Scholar
  31. 31.
    Becker U, Grønbaek M, Johansen D, Sørensen TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002;35:868–875CrossRefPubMedGoogle Scholar
  32. 32.
    Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008;295:G833–G842CrossRefPubMedGoogle Scholar
  33. 33.
    Degrace P, Moindrot B, Mohamed I, Gresti J, Clouet P. Moderate consumption of beer reduces liver triglycerides and aortic cholesterol deposit in LDLr−/− apoB100/100 mice. Atherosclerosis 2006;189:328–335CrossRefPubMedGoogle Scholar
  34. 34.
    Pischon T, Girman CJ, Rifai N, Hotamisligil GS, Rimm EB. Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr 2005;81:780–786PubMedGoogle Scholar
  35. 35.
    You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005;42:568–577CrossRefPubMedGoogle Scholar
  36. 36.
    Liu B, Balkwill A, Reeves G, Beral V, Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ 2010;340:c912CrossRefPubMedGoogle Scholar
  37. 37.
    Bechmann LP, Zahn D, Gieseler RK, Fingas CD, Marquitan G, Jochum C, et al. Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatol Res 2009;39:601–608CrossRefPubMedGoogle Scholar
  38. 38.
    Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436–2443CrossRefPubMedGoogle Scholar
  39. 39.
    Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082–1090CrossRefPubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2013

Authors and Affiliations

  • Akio Moriya
    • 1
  • Yoshiaki Iwasaki
    • 2
    • 3
  • Souhei Ohguchi
    • 4
  • Eizo Kayashima
    • 4
  • Tadahiko Mitsumune
    • 4
  • Fusao Ikeda
    • 3
  • Masaharu Ando
    • 1
  • Kazuhide Yamamoto
    • 3
  1. 1.Department of MedicineMitoyo General HospitalKanonjiJapan
  2. 2.Health Service CenterOkayama UniversityOkayamaJapan
  3. 3.Department of Gastroenterology and HepatologyOkayama University Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayamaJapan
  4. 4.Junpukai Health Maintenance CenterOkayamaJapan

Personalised recommendations